Detailed view for LmjF.36.0060

Basic information

TDR Targets ID: 21900
Leishmania major, L-ribulokinase, putative
Source Database / ID:  TriTrypDB  GeneDB

pI: 7.8178 | Length (AA): 563 | MW (Da): 61239 | Paralog Number: 0

Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0

Druggability Group : DG1

Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable

Pfam domains

PF00370   FGGY family of carbohydrate kinases, N-terminal domain
PF02782   FGGY family of carbohydrate kinases, C-terminal domain

Gene Ontology

Mouse over links to read term descriptions.
GO:0019569   L-arabinose catabolic process to xylulose 5-phosphate  
GO:0016773   phosphotransferase activity, alcohol group as acceptor  
GO:0008741   ribulokinase activity  
GO:0005524   ATP binding  
GO:0019572   L-arabinose catabolic process  
GO:0005975   carbohydrate metabolic process  

Structural information

Modbase 3D models:

There are 4 models calculated for this protein. More info on these models, including the models themselves is available at: Modbase

Target Beg Target End Template Template Beg Template End Identity Evalue Model Score MPQS zDope
8 562 1bu6 (O) 3 499 18.00 0 1 1.06 -0.2
9 552 3qdk (A) 5 534 33.00 0 1 1.36455 -0.3
9 562 2d4w (A) 3 501 17.00 0 1 1.04631 0.66
310 369 1ujn (A) 31 98 38.00 0.13 0.61 0.365972 0.43

Help me make sense of these data.

Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)

A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.

PDB Structures:

No structure availble in the PDB for this protein

Expression

Upregulation Percent Ranking Stage Dataset
Upper 60-80% percentile metacyclic. Fernandes MC
Upregulation Percent Ranking Stage Dataset
Mid 40-60% percentile amastigotes. Fernandes MC
Show/Hide expression data references
  • Fernandes MC Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures.

Orthologs

Ortholog group members (OG5_128934)

Species Accession Gene Product
Arabidopsis thaliana AT4G30310   FGGY family of carbohydrate kinase
Candida albicans CaO19.10251   potential carbohydrate kinase similar to S. cerevisiae YDR109C
Candida albicans CaO19.2737   possible carbohydrate kinase similar to S. cerevisiae YDR109C
Drosophila melanogaster Dmel_CG11594   CG11594 gene product from transcript CG11594-RC
Escherichia coli b0063   L-ribulokinase
Homo sapiens ENSG00000172456   FGGY carbohydrate kinase domain containing
Leishmania donovani LdBPK_360060.1   L-ribulokinase, putative
Leishmania infantum LinJ.36.0060   L-ribulokinase, putative
Leishmania major LmjF.36.0060   L-ribulokinase, putative
Leishmania mexicana LmxM.36.0060   L-ribulokinase, putative
Mus musculus ENSMUSG00000028573   FGGY carbohydrate kinase domain containing
Oryza sativa 4328488   Os02g0177900
Saccharomyces cerevisiae YDR109C   putative phosphotransferase
Trypanosoma cruzi TcCLB.509759.10   L-ribulokinase, putative
Trypanosoma cruzi TcCLB.508625.150   L-ribulokinase, putative

Essentiality

No essentiality data collected for this gene and/or its orthologs.

Phenotypes and Validation (curated)

We have no manually annotated phenotypes for this target. What does this mean? / Care to help?

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.

In any case, if you have information about papers containing relevant validation data for this target, please contact us.

Annotated validation

No validation data for this target

Associated compounds / Druggability

Known modulators for this target

No chemical compounds associated to this gene

Predicted associations

By orthology with druggable targets
Non orthologous druggable targets
By sequence similarity to non orthologous druggable targets
No additional associated druggable targets
Obtained from network model
No druggable targets predicted through repurposing network model

Assayability

Assay information

No assay information for this target.

Reagent availability

No reagent availability information for this target.

Bibliographic References

No literature references available for this target.

If you have references for this gene, please enter them in a user comment (below) or Contact us.

User comments

No user comments are available for this gene. Log in to add comments, or register.

Enter your comment

User ()
Gene identifier LmjF.36.0060 (Leishmania major), L-ribulokinase, putative
Title for this comment
Comment